Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria

Trial Profile

Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Aliskiren (Primary)
  • Indications Diabetic nephropathies; Hypertension
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms ASPIRE-HIGHER; AVOID
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 24 Sep 2010 Results from the sub-study that investigated the effect of treatment on renal function presented at the 46th Annual Meeting of the European Association for the Study of Diabetes
    • 24 Oct 2009 Results of an economic analysis were presented at the 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 07 Sep 2008 Results have been presented at EASD 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top